Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Biomarker Panel Characterizes Rare Phyllodes Breast Tumors

By LabMedica International staff writers
Posted on 27 Jan 2015
Cancer researchers have established a panel of biomarkers that characterizes the rare phyllodes form of breast tumors.

Phyllodes tumors are rare fibroepithelial tumors that represent about 1% of all breast tumors. More...
While most phyllodes tumors are benign, they do have the potential to become metastatic, and little is known about the genetic alterations that drive tumor initiation and/or progression.

To better understand the genetic underpinning of phyllodes tumors, investigators at the University of Michigan (Ann Arbor, USA) used targeted next-generation sequencing (NGS) techniques to identify somatic alterations in formalin fixed paraffin embedded (FFPE) patient specimens from malignant, borderline, and benign cases.

NGS revealed mutations in mediator complex subunit 12 (MED12) affecting the G44 hotspot residue in the majority (67%) of cases spanning all three histological grades. In addition, loss-of-function mutations in the p53 (TP53) oncogene as well as deleterious mutations in the tumor suppressors retinoblastoma (RB1) and neurofibromin 1 (NF1) were identified exclusively in malignant tumors. High-level copy number alterations (CNAs) were nearly exclusively confined to malignant tumors, including potentially treatable gene amplifications in EGFR (epidermal growth factor receptor) and IGF1R (insulin-like growth factor 1 receptor).

"We know little about the biology of phyllodes tumors. In part, they have not been studied much because it is difficult to accumulate a large number of samples. Using these new sequencing techniques, we were able to study archived tissue samples, which allowed us to identify enough samples to perform a meaningful analysis," said senior author Dr. Scott A. Tomlins, assistant professor of pathology and urology at the University of Michigan. "Even though phyllodes tumors are rare, it is important to have good treatment options for the aggressive cases. The first step is to understand the underlying biology of these tumors. Further study and validation is needed, but our work has identified several promising targets involved in phyllodes tumors."

The study was published in the January 15, 2015, online edition of the journal Molecular Cancer Research.

Related Links:
University of Michigan


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.